Adding pembrolizumab to chemoradiotherapy improves survival in newly diagnosed locally advanced cervical cancer. Despite that, the addition of the immunotherapy was not found to be cost-effective at a ...
Regeneron (REGN) has announced a failure in a late-stage trial designed to evaluate a combination therapy involving its ...
The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) or pembrolizumab and berahyaluronidase alfa-pmph ...
Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA ...
The FDA has approved enfortumab vedotin (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, Merck) or subcutaneous pembrolizumab (Keytruda Qlex, Merck) for the neoadjuvant and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results